Latest news with #SeanMcGowan
Business Insider
a day ago
- Business
- Business Insider
Roth MKM Reaffirms Their Buy Rating on GURU Organic Energy Corp (GUROF)
Roth MKM analyst Sean McGowan maintained a Buy rating on GURU Organic Energy Corp (GUROF – Research Report) today and set a price target of C$3.75. The company's shares closed last Thursday at $1.40. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, McGowan is a 4-star analyst with an average return of 14.4% and a 48.21% success rate. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GURU Organic Energy Corp with a $2.29 average price target.
Business Insider
18-05-2025
- Business
- Business Insider
Roth MKM Keeps Their Buy Rating on Reed's (REED)
Roth MKM analyst Sean McGowan maintained a Buy rating on Reed's (REED – Research Report) today and set a price target of $2.00. The company's shares closed last Friday at $1.18. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, McGowan is ranked #1970 out of 9519 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Reed's with a $2.00 average price target. Based on Reed's' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $9.73 million and a GAAP net loss of $4.12 million. In comparison, last year the company earned a revenue of $11.69 million and had a GAAP net loss of $6.6 million
Yahoo
02-04-2025
- Business
- Yahoo
Amneal and Shilpa introduce Boruzu in US for cancer treatment
Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or intravenous administration, offering a ready-to-use option for patients with multiple myeloma and mantle cell lymphoma in the US. Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma, and lowers the compounding preparation process needed for administration. A proteasome inhibitor, Boruzu references branded Velcade, a lyophilised powder that needs reconstitution before usage. Shilpa has created the molecule, while Amneal will handle the manufacturing and commercialisation of the product. The most commonly reported adverse events for Boruzu in clinical studies have been anaemia, anorexia, asthenic conditions, diarrhoea, euralgia, gastrointestinal issues, leukopenia, neutropenia, peripheral neuropathy, psychiatric disorders, pyrexia, reduced appetite and thrombocytopenia. Amneal pharmaceutical biosimilars and branded oncology senior vice-president Sean McGowan stated: "As we advance our broader strategy to build a leading injectables portfolio with durable, high-impact complex products, we are excited to announce the US launch of Boruzu in our oncology portfolio. 'This ready-to-use injectable marks a significant innovation for our customers by streamlining pharmacy preparation steps for clinicians while now carrying a unique J-code to facilitate reimbursement.' Amneal is a biopharmaceutical company based in Bridgewater, US. Through its affordable medicines segment, the company focuses on widening complex product categories as well as therapeutic areas, which include biosimilars and injectables. In its speciality segment, Amneal has a branded pharmaceutical portfolio focusing mainly on endocrine and central nervous system disorders. The company distributes pharmaceuticals and other products to the federal government of the US, as well as to institutional and retail markets, via its AvKARE segment. An integrated pharmaceutical group, Shilpa has business interests in peptides, oncology and non-oncology active pharmaceutical ingredients, differentiated finished dosage formulations and polymers. It also offers contract development and manufacturing organisation services to pharmaceutical firms, supported by research and development and manufacturing capabilities. In August 2024, the US Food and Drug Administration (FDA) approved Amneal's Crexont extended-release capsules for treating Parkinson's disease. "Amneal and Shilpa introduce Boruzu in US for cancer treatment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
01-04-2025
- Business
- Yahoo
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
- First ready-to-use, subcutaneous formulation of Bortezomib now available - Marks Amneal's fourth 505(b)(2) injectable product launch in the last year BRIDGEWATER, N.J., April 01, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and Shilpa Medicare Limited ("Shilpa") today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade®, a lyophilized powder requiring reconstitution before use. Shilpa developed the molecule and Amneal will manufacture and commercialize the product. BORUZU has a unique J-code. "As we advance our broader strategy to build a leading injectables portfolio with durable, high-impact complex products, we are excited to announce the U.S. launch of BORUZU™ in our oncology portfolio. This ready-to-use injectable marks a significant innovation for our customers by streamlining pharmacy preparation steps for clinicians while now carrying a unique J-code to facilitate reimbursement. Our commitment remains steadfast in delivering differentiated oncology products that enhance patient care and access," said Sean McGowan, Senior Vice President, Biosimilars and Branded Oncology. "This second NDA product being launched in the US market from our novel injectable portfolio demonstrates our capabilities and commitment to introduce pharmacy efficient solutions that enhance compliance and have the potential to reduce patient wait times. This development exemplifies Shilpa's constant endeavor to work towards introducing novel first of its kind pharmaceutical products that help improve the healthcare requirements of a large patient pool," said Vishnukant Bhutada, Managing Director of Shilpa Medicare. The most commonly reported adverse reactions for BORUZU™ in clinical studies include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia and anemia. For full prescribing information, see package insert located here. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit and follow us on LinkedIn. About Shilpa Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including novel injectables, orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities. For more information, please visit Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as "plans," "expects," "will," "anticipates," "estimates," and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. View source version on Contacts Investor Contact Anthony DiMeoVP, Investor Shilpa Contact Monish ShahHead Strategic & Investor Sign in to access your portfolio
